Department of Pharmaceutical Sciences, North South University, Plot # 15, Block # B, Bashundhara R/A, Dhaka-1229, Bangladesh.
Division of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona, United States.
Curr Drug Discov Technol. 2021;18(3):354-364. doi: 10.2174/1570163817666200312102137.
Most of the clinical approved protein-based drugs or under clinical trials have a profound impact on the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of the therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to enhance specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will focus on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.
大多数已临床批准的蛋白质类药物或正在临床试验中的药物对治疗重大疾病具有深远影响。哺乳动物真核细胞培养方法,特别是 CHO(中国仓鼠卵巢)细胞,主要用于生物制药行业,用于大规模生产治疗性蛋白质。最近在 CHO 细胞生物加工方面的进展使得能够表达高质量的蛋白质。细胞系的发展有可能提高特定的生产力。因此,它为全球学术界和工业界的研究人员提供了一个有趣的领域。本文综述了哺乳动物 CHO 细胞培养技术的最新进展,以及进一步大规模生产蛋白质治疗药物的未来发展前景。